PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE) Following 4Q
January 29, 2020 7:04 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $53.00 price target on Pfizer (NYSE: PFE) following the company's 4Q earnings report. PFE reported 4Q19 adjusted diluted EPS of $0.55, $0.03 lower than consensus.
PFE presented its 2020 sales and EPS guidance of $48.5-50.5B and... More
Pfizer (PFE) CEO, Never Says Never, But We Don't Want Big M&A - Bloomberg, Citing Call
January 28, 2020 10:59 AM ESTPfizer (NYSE: PFE) CEO, Never Says Never, But We Don't Want Big M&A - Bloomberg, Citing Call
Pfizer (PFE) Misses Q4 EPS by 2c, Offers FY20 Guidance
January 28, 2020 6:47 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.55, $0.02 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $12.7 billion versus the consensus estimate of $12.61 billion.
GUIDANCE:
Pfizer sees FY2020 EPS of $2.82-$2.92, versus the consensus of $2.90. Pfizer sees... More
